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OBJECTIVES The goal of this study was to investigate the presence of myocardial cell damage in patients
with systemic hypertension and its relationship with left ventricular hypertrophy (LVH).
BACKGROUND Although initially compensatory, LVH adversely affects myocellular integrity and contributes
to congestive heart failure in hypertensive patients. Noninvasive detection of myocardial
damage can be of value.
METHODS We performed imaging studies with 111In-labeled monoclonal antimyosin antibodies to
identify myocardial damage in 39 patients with systemic hypertension and variable degrees of
LVH. Three groups were considered: 16 asymptomatic patients with normal echocardio-
graphic left ventricular mass (LVM) (group I); 14 asymptomatic patients with LVH (group
II) and 9 patients with symptomatic hypertensive heart disease and advanced LVH (group
III). The severity of myocardial damage was represented as heart-to-lung (target-to-
background) antibody uptake ratio (normal: ,1.55).
RESULTS Mean LVM index was 105 6 14 g/m2 in group I, 124 6 24 in group II and 174 6 29 in
group III. Heart-to-lung ratios of antimyosin uptake were: 1.45 6 0.14 in group I, 4 of the
16 (25%) patients showing an abnormal scan; 1.50 6 0.07 in group II with abnormal scans
in 2 of the 14 (16%) patients and 1.77 6 0.16 (p , 0.001) in group III, all 9 patients
presenting with abnormal antimyosin scans. On multivariate regression analysis LVM index
was the main variable that independently correlated with the degree of myocardial uptake of
antimyosin (r 5 0.815; p 5 0.001).
CONCLUSIONS This study provides the first in vivo evidence of myocyte damage in patients with
hypertension. The severity of myocardial damage can be related to the magnitude of LVH.
(J Am Coll Cardiol 2000;36:2198–203) © 2000 by the American College of Cardiology
Hypertension is one of the most important risk factors for
left ventricular hypertrophy (LVH) and congestive heart
failure (1–3). Increasing levels of systolic blood pressure
have been reported to be associated with progressively
increasing echocardiographic left ventricular mass (LVM)
(4,5). Although LVH may be associated with supernormal
ventricular ejection phase indexes (6), both exercise-induced
depression in systolic function (7,8) and a depressed midwall
fractional shortening/end-systolic stress relationship (9) in a
large proportion of patients with hypertension suggest that
LVH may actually result in systolic dysfunction. It is logical
to assume that a loss of cardiomyocytes should precede
deterioration in myocardial systolic function. Myocyte loss
occurs late in the natural history of hypertension and has
been demonstrated to correlate with the degree of LVH in
necropsy specimens (10,11).
The role of myocardial damage in the progression of
LVH to heart failure in hypertensive patients has not been
specifically evaluated. This study was designed to determine
the prevalence and severity of myocardial damage of patients
with hypertension by means of noninvasive imaging with
antimyosin antibody radiolabeled with indium-111. The
antimyosin antibody directed specifically against cardiac
myosin only accumulates in the necrotic myocytes that have
lost the sarcolemmal integrity, thereby exposing intracellular
myosin to extracellular milieu (12–14). This method has
been extensively used in the detection of diffuse myocardial
damage in several cardiac conditions (15–22).
METHODS
Patients. Thirty-nine patients, 14 men and 25 women,
mean age of 55 6 11 years, with varying degrees of systemic
hypertension were included in this study. Of them, 30
consecutive asymptomatic patients were recruited from the
outpatient clinic of the Hypertension Unit. All patients had
documented primary hypertension of variable degrees and
were being followed-up and treated by the Hypertension
Unit staff for at least one year. While 16 of these 30 patients
(group I) had normal echocardiograms, 14 patients (group
II) demonstrated echocardiographic evidence of LVH. The
diagnosis of LVH was entertained when the indexed LVM
exceeded the upper normal limits in our laboratory
(.123 g/m2 in men and .109 g/m2 in women), applying
the echocardiographic methods detailed below. None of the
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patients had any clinical or investigative evidence of second-
ary hypertension. Regarding other coronary risk factors, 6 of
30 were past smokers, 8 had high total cholesterol blood
levels under treatment, and none were diabetics. Coronary
artery disease was deemed unlikely in these 30 patients due
to a lack of history of chest pain in 24 and in 6 who related
symptoms consistent with angina because either coronary
angiography (2 cases) or myocardial perfusion scintigraphy
(4 cases) was normal. Hypertension was adequately con-
trolled in all patients at the time of the study: 6 were
receiving a beta-adrenergic blocking agent alone, 11 were on
calcium channel blockers, and the remaining 13 patients
received a combined therapy including these drugs and, in
some cases, thiazide diuretics.
The remaining 9 of the 39 patients (group III) had a
history of long-term hypertension and were admitted to the
hospital either for evaluation of chest pain (3 patients) or
heart failure (6 patients); coronary arteries were angio-
graphically normal in these 9 patients, and none had
valvular or congenital heart disease to account for the
clinical manifestations. None of the patients had a history of
alcohol abuse or consumed potentially cardiotoxic drugs.
Hypertension was found to be poorly controlled in all nine
patients at the time of hospital admission. All of these nine
patients were receiving a combination therapy including two
or more of the following: diuretics, digoxin, calcium channel
blockers, nitrates and vasodilators other than angiotensin-
converting enzyme (ACE) inhibitors.
Antimyosin imaging was performed in all patients for the
detection and assessment of the severity of myocardial
damage. The protocol of this study was approved by the
institutional ethics committee and research review board.
All patients voluntarily agreed to participate in the study
and signed a consent form before antimyosin imaging.
Echocardiography and cardiac catheterization. Two-
dimensional echocardiography guided M-mode tracings
were obtained, and left ventricular chamber dimensions
(both systolic and diastolic) and wall thickness (septal and
posterior) were measured with a pair of electronic calipers in
accordance with the recommendations of the American
Society of Echocardiography (23). From these measure-
ments, LVM and ejection fraction were calculated as de-
scribed elsewhere (24,25). Coronary angiography was per-
formed for patients who were admitted to the hospital
(group III) in order to rule out coronary artery disease as the
cause of chest pain or congestive heart failure.
Antimyosin imaging and quantitative analysis of anti-
body uptake. Commercially available antimyosin antibody,
R11D10-Fab-DTPA (500 mg) (Centocor, Leiden, Neth-
erlands) was labeled with 2 mCi of indium-111 before
intravenous administration to all patients. Planar images
were obtained 48 h later with a large field-of-view gamma
camera equipped with a medium energy collimator. Pulse
height analyzers were set at the center lines of 173 and
247 keV with a 20% window for each peak. The images
were obtained in the anterior and 60 to 70° left anterior
oblique views for a minimum of 500,000 counts between 5
to 10 min and stored in a dedicated computer for subse-
quent analysis. Interpretation of antimyosin studies was
performed by an independent observer who was blinded to
the clinical and echocardiographic findings. Quantitative
uptake was determined by calculating heart-to-lung count
density ratio (HLR) of antimyosin uptake obtained from
dividing average counts per pixel in the cardiac region of
interest by average counts per pixel in area of interest set at
right lung. Heart-to-lung count density ratio of antimyosin
uptake up to 1.55 was considered to be normal; this limit
was established as 2 standard deviations higher than the
mean HLR observed in a series of normal individuals
studied at our laboratory and as reported previously (15).
Statistical analysis. All results were expressed in mean 6
standard deviation. Analysis of variance was performed for
the comparison of continuous clinical, echocardiographic
and scintigraphic variables, followed by Newman Keul’s
multiple range test for the assessment of pairwise signifi-
cance. Correlation coefficient was estimated between anti-
myosin uptake and all continuous variables and between
LVH and potential confounders of the former relationship.
Of the variables that correlated because they intervened in
equations leading to third calculated variables, those with
the best correlation coefficient were used. Changes in
correlation coefficients were assessed by 95% confidence
interval. Multiple linear regression analysis was performed
to assess the effect of LVH on the degree of antimyosin
uptake adjusting for potentially confounding factors. Con-
founding variables were selected from the table of bivariate
correlation coefficients between antimyosin uptake and con-
tinuous variables, which showed a p value lower than 0.10.
Variables necessary to calculate LVM index and ejection
fraction were disregarded. Chi-square or Fisher exact test, as
appropriate, was applied for categorical variables.
RESULTS
Clinical and echocardiographic characteristics (Table 1).
The mean age and body surface area of patients in the three
groups were similar. Patients in groups I (hypertensive
patients without LVH) and II (hypertensive patients with
LVH) showed adequately controlled systolic and diastolic
blood pressure levels; hypertension was poorly controlled in
group III patients (hypertensive patients with LVH). Pa-
tients in groups I and II were asymptomatic. Of the nine
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
HLR 5 heart-to-lung ratio (of antimyosin uptake)
LVH 5 left ventricular hypertrophy
LVM 5 left ventricular mass
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patients of group III, three were in New York Heart
Association functional class II, two in functional class III,
and the remaining four were in New York Heart Associa-
tion class IV.
Group I patients had normal echocardiograms with
normal septal and posterior left ventricular wall thickness,
end-diastolic and end-systolic diameter, ejection fraction
and LVM index. Group II patients had normal left ventric-
ular size and ejection fraction but showed significantly
increased septal and posterior wall thickness and, conse-
quently, increased LVM index. Group III patients showed
significantly increased left ventricular cavity dimensions and
septal and posterior wall thickness as well as LVM index;
ejection fraction was lower compared with groups I and II
(p , 0.0001).
Evaluation of myocardial damage (Table 1). Abnormal
antimyosin scans were observed in 4 of the 16 patients of
group I (25%) and in 2 of the 14 patients (15%) of group II.
All nine patients (100%) of group III demonstrated an
abnormal antimyosin scan. The HLR in group III (1.77 6
0.16) was significantly higher than it was in groups I and II
(1.45 6 0.14 and 1.50 6 0.07, respectively). The abnormal
antimyosin scans always demonstrated a diffuse pattern of
myocardial uptake of antimyosin antibody.
Correlation coefficients were calculated to evaluate pos-
sible clinical and echocardiographic variables associated
with myocardial uptake of antimyosin (Table 2). Left
ventricular cavity dimensions and posterior wall thickness
showed correlation coefficients higher than 0.5, while an
inverse correlation with ejection fraction was found (r 5
20.68) (Fig. 1); the indexed LVM demonstrated the
highest correlation coefficient (r 5 0.72), which increased to
0.81 when only patients with left ventricular hypertrophy
(groups II and III) were considered. The relationship
Figure 1. The correlation between left ventricular ejection fraction and the
severity of myocardial damage detected by antimyosin antibody heart-to-
lung uptake ratio in those 36 patients in whom reliable measures of ejection
fraction by echocardiography were obtained. The area below the horizon-
tal line represents normal range of antimyosin antibody heart-to-lung
uptake ratio (,1.55). LV 5 left ventricular.
Table 2. Correlation of Antimyosin Uptake Heart-to-lung Ratio





r p r p
Age (yrs) 0.381 0.017 0.332 0.122
SBP (mm Hg) 0.303 0.086 0.247 0.281
LVID, end-diastolic (mm) 0.462 0.003 0.498 0.016
LVID, end-systolic (mm) 0.632 0.001 0.770 0.001
IVS (mm) 0.314 0.051 0.182 0.451
PW (mm) 0.561 0.001 0.556 0.006
LVEF 20.683 0.001 20.863 0.001
LV mass index (g/m2) 0.718 0.001 0.813 0.001
IVS 5 interventricular septum; LV 5 left ventricle; LVEF 5 left ventricular ejection
fraction; LVH 5 left ventricular hypertrophy; LVID 5 left ventricular internal
diameter; PW 5 posterior wall; SBP 5 systolic blood pressure.
Table 1. Clinical, Echocardiographic and Scintigraphic Characteristics of the Total Study Group
(n 5 39)
Group I Group II Group III p I vs. II I vs. III II vs. III
Number of patients 16 14 9
Age (yrs) 53 6 9 56 6 11 61 6 11 0.1674
SBP (mm Hg) 138 6 12 136 6 16 178 6 36 0.0002 * *
DBP (mm Hg) 89 6 10 87 6 11 103 6 19 0.0363 * *
Body surface area (m2) 1.79 6 0.18 1.82 6 0.19 1.81 6 0.16 0.9407
LVID, end-diastolic
(mm)
46 6 4 48 6 4 54 6 7 0.0025 * *
LVID, end-systolic
(mm)
29 6 4 28 6 4 42 6 11 0.0000 * *
IVS (mm) 11 6 1 13 6 2 14 6 2 0.0001 * *
PW (mm) 10 6 1 12 6 1 13 6 2 0.0000 * * *
LVEF 0.68 6 0.05 0.71 6 0.06 0.44 6 0.18 0.0000 * *
LV mass index (g/m2) 105 6 14 124 6 24 174 6 29 0.0000 * * *
Antimyosin uptake
(HLR)
1.45 6 0.14 1.50 6 0.07 1.77 6 0.16 0.0000 * *
Abnormal AM scan 4/16 (25%) 2/14 (15%) 9/9 (100%) 0.0007 * *
*Pair-wise statistical significance from Newman-Keul’s multiple range test analysis. p 5 statistical significance of analysis of
variance between the three groups.
AM 5 antimyosin; DBP 5 diastolic blood pressure; HLR 5 heart-to-lung ratio; IVS 5 interventricular septum; LV 5 left
ventricle; LVEF 5 left ventricular ejection fraction; LVID 5 left ventricular internal diameter; PW 5 posterior wall; SBP 5
systolic blood pressure.
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between LVM index and HLR of antimyosin uptake is
shown in Figure 2.
The adjusted correlation coefficient obtained in multiple
linear regression analysis was 0.81, predominantly due to
LVM index. Residual correlation coefficients of left ventric-
ular ejection fraction, age and systolic blood pressure were
not statistically significant in the stepwise analysis and made
minor contributions to the equation (Table 3).
DISCUSSION
Antimyosin studies in the assessment of myocardial cell
damage. This study constitutes the first in vivo evidence of
diffuse myocardial damage in hypertensive patients. The
method employed, the myocardial uptake of indium-111
labeled monoclonal antimyosin antibodies, provides the
only available means to detect noninvasive myocardial cell
necrosis (12–14). Conceptually, uptake of antimyosin anti-
bodies implies that, at the time of the study, an ongoing
myocardial necrosis is taking place (18). In clinical studies
myocardial uptake has been equated with the presence of
biopsy-proven myocardial damage (17,21); the intensity of
such uptake correlates with the degree of damage (26), and
patients with very intense uptake show adverse clinical
outcomes, as reported in myocarditis (15,16), cardiac rejec-
tion after transplantation (17), chronic dilated cardiomyop-
athy (18,19), alcohol induced heart disease (20) and cardio-
toxicity associated with anthracycline (21) or tricyclic
antidepressant drugs (22).
Cardiomyopathy of overload. The loss of cardiomyocytes
herein reported in patients with hypertension is consistent
with the elegant observations made by Meerson (27) who
showed in an experimental model of pressure overload the
induction of a process of compensatory myocardial hyper-
trophy associated with myocyte damage. Loss of myocytes
further enhances the overload leading to progressive heart
failure (28), recent evidence suggesting that the transition
from a state of compensation to myocardial failure is related
to both cardiomyocyte loss (29) and alterations in the
metabolism of extracellular matrix (30). Occurrence of
myocardial cell death with long-standing myocardial hyper-
trophy has been termed cardiomyopathy of overload (31–
33).
LVH and myocardial cell damage. Evidence of myocyte
damage in this study was observed in a small proportion of
ambulatory patients (groups I and II) who had either none
or only mild degrees of LVH. On the other hand, all
patients with advanced hypertensive heart disease (group
III) showed evidence of such damage. Although LVM
strongly correlated with the severity of myocardial damage
(Fig. 2), the role of hypertrophy in relation to myocardial
damage must be considered with caution. First, there was no
difference in the prevalence of antimyosin uptake between
asymptomatic ambulatory patients without (group I) and
with (group II) left ventricular hypertrophy (25% vs. 15%).
Second, the presence of myocardial damage in 4 of 16
patients without hypertrophy (group I) raises the issue of
the relationship of such damage with the mere presence of
hypertrophy. For patients in group III admitted to the
hospital as a result of advanced hypertensive heart disease,
very high left ventricular mass values were detected, and
myocardial damage was 100% prevalent. The unstable
clinical situation of these patients as a group could raise the
argument that positive antimyosin scans are due to a
persistence of high blood activity of antimyosin in those
patients with markedly reduced left ventricular function, as
data from Figure 1 could suggest. We did not measure
blood clearance of 111In-labeled antimyosin antibodies from
serial blood samples in our patients. Pharmacokinetics of
antimyosin antibodies was investigated in early studies (34),
showing that mean half-life of antimyosin was 5 h and that
a negligible proportion of the initial blood activity was
present in samples drawn at 48 h, a time when imaging
could be done without risk of a false positive—or nega-
tive—myocardial scan. In addition, observations from our
own group (15) indicate that in images obtained at 48 h
from the injection, the intensity of uptake is not higher than
that observed for imaging at 72 h, both in normal individ-
uals and in patients with depressed left ventricular function.
This result suggests that a plateau of minimal blood pool
Figure 2. The correlation between the indexed LVM and the severity of
myocardial damage detected by antimyosin antibody heart-to-lung uptake
ratio in the 39 hypertensive patients. The area below the horizontal line
represents the normal range of antimyosin antibody heart-to-lung uptake
ratio (,1.55). There was a significant positive correlation between LVM
index and the HLR (r 5 0.72). Open squares 5 patients in group I (no
LVH), solid squares 5 patients in group II (asymptomatic patients with
LVH) and solid circles 5 patients in group III (symptomatic patients).
HLR 5 heart-to-lung ratio; LV 5 left ventricle; LVH 5 left ventricular
hypertrophy; LVM 5 left ventricular mass.
Table 3. Multiple Linear Regression Analysis of Heart-to-lung




LV mass index 0.4195 0.0511
LVEF 20.3685 0.0698
Age 0.2216 0.0860
Systolic blood pressure 20.0725 0.5692
Multiple regression: r 5 0.81; r2 5 0.65.
LV 5 left ventricle; LVEF 5 left ventricular ejection fraction.
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activity had already been reached at 48 h. Our previous
observation that heart failure per se does not lead to
abnormally high antimyosin uptake provided that a process
of ongoing myocardial cell loss is not present (18) also
speaks against the occurrence of false positive studies in
patients with heart failure. Finally, it has to be considered
that some of the patients in group III (three out of nine)
who also exhibited abnormally high HLR, were not hemo-
dynamically unstable.
Mechanisms of myocardial cell death. The mechanisms
leading to the death of myocytes in LVH are not well
understood. Augmented LVM and systolic pressure signif-
icantly increase intramyocardial tension and myocardial
oxygen demand, which are not accompanied by a propor-
tional increase in vascular density per unit area of hypertro-
phied myocardium. The discordance between oxygen de-
mand and supply is likely to result in relative myocardial
ischemia and myocellular death by necrosis (35–37). Re-
cently, it has been proposed that apoptosis, or programmed
cell death, may also contribute to myocardial damage in
hypertrophic hearts (29,32,38,39). Apoptosis is a form of
cell death distinct from myocyte necrosis that does not result
in an inflammatory response (40). Apoptosis in terminally
differentiated cells such as cardiomyocytes may result from
an unnatural growth response where protein synthesis is
augmented but the cell division cannot be induced (32). In
hypertension, hemodynamic load to myocytes via stretch
receptors (41) or integrin-mediated (42) mechanisms and
paracrine or autocrine stimulation of various neurohumoral
receptors (43–45) including angiotensin are likely to initiate
the cascade of compensatory ventricular hypertrophy. It is
also possible that repetitive ischemia not sufficient to result
in necrosis may induce apoptosis (39). However, despite the
established evidence of the role of apoptosis in the transition
from stable compensation to failure in the animal model
(46), this mechanism has not been shown in humans to date
(47). Although apparently contradictory, the finding of
positive antimyosine scans (which require a disrupted sar-
colemma) in hearts with apoptosis, a process in which
membrane integrity is preserved, has been observed by our
group in a series of patients with heart transplant and
allograft rejection (48).
Clinical implications. The clinical implications of the
observations presented here are important. First, our study
suggests that, at a certain stage or in certain individuals with
hypertensive heart disease, ongoing myocellular loss is
present. This could explain the progressive nature of the
disease and the clinical and epidemiological observations
that hypertension is an important cause of heart failure
(1–3). Second, the evidence of myocardial damage for
patients with apparently well controlled blood pressure
raises the issue of adequacy of management of hypertension
guided by the mere control of blood pressure. If progressive
loss of myocytes determines the development of cardiomy-
opathy, then the optimum treatment of hypertension should
consider the alleviation or suppression of myocyte damage
in addition to the control of blood pressure.
In spontaneously hypertensive rats ACE tissue levels
correlate with the presence and degree of myocyte apoptosis,
which can be prevented by treatment with ACE inhibitors
(49). In the clinical context it remains to be seen whether
pharmacologic agents such as ACE inhibitors (50,51) or
newer generations of beta-blockers (52,53) could interfere
with the mechanisms leading to myocardial cell death.
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